1. Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors

3. Program Goals

4. Idelalisib Discontinuations: Pooled Data From Phase 3 Clinical Trials[a]

5. Ibrutinib Discontinuations: Single-Center Pooled Data From 4 Clinical Trials

6. Assessing Disease Progression

7. BCR Signaling Inhibitors: Key AEs in Phase 3 Clinical Trials

8. Discontinuing BCR Signaling Inhibitors: Multicenter Clinical Practice Experience

9. Case #1: Discontinuation of Ibrutinib Due to AEs

10. Considerations in Managing Patients With Ibrutinib-Associated AEs

11. Factors Associated With Ibrutinib Failure: Single-Center Pooled Data From 4 Clinical Trials

12. Case #1: Discontinuation of Ibrutinib Due to AEs - Switch BCR Signaling Inhibitor

13. Considerations in Managing Patients With Idelalisib-Associated AEs

14. Case #2: Discontinuation of Idelalisib + Rituximab Due to Progression

15. Case #2: Discontinuation of Idelalisib + Rituximab Due to Progression (cont)

16. Factors Associated With Idelalisib Failure: Subgroup Analysis of Phase 3 Data

17. Outcomes in Patients Who Progress With Richter's Transformation on Idelalisib: Pooled Data From Phase 3 Clinical Trials

18. Outcomes in Patients Who Discontinue Idelalisib: Pooled Data From Phase 3 Clinical Trials

19. Treatment Options After Discontinuing a BCR Signaling Inhibitor

20. Survival After Switching BCR Signaling Inhibitors: Multicenter Clinical Practice Experience

21. Venetoclax After Idelalisib or Ibrutinib: Ongoing Phase 2 Trial

22. Investigational Approaches With Venetoclax

23. BTK Inhibitors in Development

24. Role of Allogeneic Stem Cell Transplantation

25. Potential Role of CAR T-Cell Therapy

26. Case #1: Discontinuation of Idelalisib Due to Disease Progression - Final Follow-Up

27. Venetoclax + Rituximab in Patients With R/R CLL: Phase 1b Long-Term Data

28. Conclusions

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. Abbreviations (cont)